Chembio Diagnostics to Report First Quarter 2021 Financial Results on May 6, 2021

Rhea-AI Summary

Chembio Diagnostics (CEMI) will announce its first-quarter 2021 financial results on May 6, 2021, after trading hours. A conference call hosted by the management team is scheduled for 4:30 PM ET that same day. Investors can listen in via a US number (877-545-0320) or an international number (973-528-0016) using Entry Code: 562459. Chembio focuses on point-of-care diagnostics for infectious diseases, including COVID-19, and its products are sold globally through various channels.

Positive

• Scheduled announcement of first-quarter 2021 financial results, indicating transparency.
• Focus on point-of-care diagnostics, a growing market segment.
• Global product reach across multiple distribution channels.

Negative

• None.

HAUPPAUGE, N.Y., April 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2021 after the close of trading on Thursday, May 6, 2021.

The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on May 6, 2021. Investors interested in listening to the conference call may do so by dialing 877-545-0320 from the US or 973-528-0016 from outside the US and providing Entry Code: 562459 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 40896 or by accessing www.chembio.com/investors/calendar-of-events/.

About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.

DPP is Chembio’s registered trademark, and the Chembio logo is Chembio’s trademark. For convenience, these trademarks appear in this release without ® or ™ symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademarks.

Investor contact:
Philip Taylor
Gilmartin Group
(415) 937-5406
investor@chembio.com

 

FAQ

When will Chembio Diagnostics release its financial results for Q1 2021?

Chembio Diagnostics will release its first-quarter 2021 financial results on May 6, 2021, after market close.

What time is the Chembio Diagnostics conference call scheduled for?

The conference call is scheduled for May 6, 2021, at 4:30 PM Eastern Time.

How can I listen to the Chembio conference call?

You can listen to the conference call by dialing 877-545-0320 from the US or 973-528-0016 from outside the US, using Entry Code: 562459.

What is Chembio Diagnostics' focus in the healthcare market?

Chembio Diagnostics specializes in point-of-care diagnostics for infectious diseases, including COVID-19.